Investor Relations

EternoGen has received an accumulated investment of about $9M which has driven product development and optimization, and is presently raising a series B round.

Present investors include angel investors, management team members, a technology incubator, and a major European pharmaceutical company.

Current investors include:

logo-centennial-investors       logo-advancing-missouri

logo-arch-grants         logo-sinclair-research         logo-mtc

Commercialisation in Europe and Asia

EternoGen is currently seeking commercialising of RPC Pure Collagen in Europe. EternoGen’s success factors are:

  • Large and rapidly growing market
  • Clear customer and consumer need
  • Superior and unique technology
  • Experienced team
  • Attractive acquisition target

For more information

Please contact us.